Abstract
The extensive use of selective histamine H2 receptor antagonists provides a unique opportunity to describe very rare adverse drug reactions.
Although mild elevation of serum creatinine level following the administration of cimetidine is relatively common, acute interstitial nephritis (AIN) is a rare hypersensitivity reaction. There have been 25 published reports of AIN associated with H2 antagonist therapy and we also identified 16 cases from the Australian Adverse Drug Reaction Advisory Committee (ADRAC) database. AIN was reported most commonly following cimetidine administration. AIN was supported by renal biopsy in 28 patients and by rechallenge in 6. H2 antagonist—induced AIN was more commonly reported in men older than 50 years. In the majority of cases the onset was within 2 weeks of initiation of therapy (1 day to 11 months). The clinical manifestations were nonspecific including sterile pyuria, elevated erythrocyte sedimentation rate, fatigue, proteinuria and leucocytosis whereas rash, arthralgia and flank pain were rarely reported.
There were 170 cases of hepatotoxicity following H2 antagonist administration reported to ADRAC. These were more common following ranitidine and included cholestatic, hepatocellular and mixed reactions. Hepatotoxicity was proven following liver biopsy in several cases published in the literature and in 15 cases reported to ADRAC. Hepatotoxicity recurred upon rechallenge in 6 cases.
Generally, renal and hepatic adverse effects resolved quickly after cessation of H2 antagonist therapy and did not require specific treatment. Nephrotoxicity and hepatotoxicity following administration of an H2 antagonist is rare and a high index of suspicion is necessary for early detection. Now that many H2 antagonists are available over the counter, awareness of these conditions and early detection with cessation of H2 antagonist therapy would appear paramount.
Similar content being viewed by others
References
Folkow B, Haeger K, Kahlson G. Observations on reactive hyperaemia as related to histamine, on drugs antagonising vasodilation induced by histamine and on vasodilator properties of adenosine triphosphate. Acta Physiol Scand 1948; 15: 264–78
Black JW, Duncan WAM, Durant GJ, et al. Definition and antagonism of histamine H2-receptors. Nature 1972; 236: 385–90
Duncan WAM, Parsons ME. Reminiscenses of the development of cimetidine. Gastroenterology 1980; 78: 620–25
Freston JW. Cimetidine. Developments, pharmacology, and efficacy. Ann Intern Med 1982; 97: 573–80
Gantz I, Schaffer M, DelValle J, et al. Molecular cloning of a gene encoding the histamine H2 receptor. Proc Natl Acac Sci 1991; 88: 429–33
Hersey SJ, Sachs G. Gastric acid secretion. Physiol Rev 1995; 75: 155–90
Dell Valle J, Gantz I. Novel insights into histamine H2 receptor biology. Am J Physiol 1997; 273: G 987–96
Brimblecombe RW, Duncan WAM, Durant GJ. Characterization and development of cimetidine as a histamine H2-receptor antagonist. Gastroenterology 1978; 74: 339–47
Hirschowitz BI. H2 histamine receptors. Ann Rev Pharmacol Toxicol 1979; 19: 203–44
Blackwood WS, Maudgal DP, Pickard RG. Cimetidine in duodenal ulcer. Lancet 1976; II: 174–6
Freston JW. Cimetidine: adverse reactions and patterns of use. Ann Intern Med 1982; 97: 728–34
Kruss DM, Littman A. Safety of cimetidine. Gastroenterology 1978; 74: 478–83
Schunack W. What are the differences between the H2-receptor antagonists? Aliment Pharmacol Ther 1987; 1: 493S–503S
Zeldis JB, Friedman L, Isselbacher KJ. Ranitidine: a new H2-receptor antagonist. N Engl J Med 1983; 309: 1368–73
Vial T, Goubier C, Bergeret A, et al. Side effects of ranitidine. Drug Saf 1991; 6: 94–117
Gifford LM, Aeugle ME, Myerson RM, et al. Cimetidine postmarket outpatient surveillance program: interim report on phase 1. JAMA 1980; 243: 1532–5
Haggie SJ, Fermont DC, Wylie JH. Treatment of duodenal ulcer with cimetidine. Lancet 1976; I: 983
Burland WL, Gleadle RI, Mills JG. Proceedings of the Second International Symposium of Histamine H2-Receptor Antagonists. In: Burland WL, Simkins MA, editors. Exerpta Medica: Amsterdam and Oxford, 1977: 67–73
Larsson R, Bodemar G, Kagedal B. The effect of cimetidine, a new histamine H2-receptor antagonist, on renal function. Acta Medica Scand 1979; 205: 87–9
Davis TG, Pickett DL, Schlosser JH. Evaluation of a worldwide spontaneous reporting system with cimetidine. JAMA 1980; 243: 1912–4
Handa SP. Drug-induced acute interstitial nephritis: report of 10 cases. Can Med Assoc J 1986; 135: 1278–82
Linton AL, Clark WF, Driedger AA, et al. Acute interstitial nephritis due to drugs. Ann Intern Med 1980; 93: 735–41
Droz D, Kleinknecht D. In: Davison AM, Cameron JS, Grünfeld JP, et al, editors. Oxford textbook of clinical nephrology. 2nd edition. New York (NY): Oxford University Press, 1998: Vol 2, 1634–48
Black M. Hepatotoxic and hepatoprotective potential of histamine (H2) receptor antagonists. Am J Med 1987; 83(6A): 68–75
Van Steenbergen W, Vanstapel MJ, Desmet V, et al. Induced liver injury. Report of three cases. J Hepatol 1985; 1: 359–68
Bodemar G, Walan A. Maintenance treatment of recurrent peptic ulcer by cimetidine. Lancet 1978; I: 403–7
Dutt MK, Moody P, Northfield TC. Effect of cimetidine on renal function in man. Br J Clin Pharmacol 1981; 12: 47–50
Burgess E, Blair A, Krichman K. Inhibition of renal creatinine secretion by cimetidine in humans. Renal Physiol 1982; 5: 27–30
Sharpe PC, Hawkins BW. Proceedings of the Second International Symposium of Histamine H2-Receptor Antagonists. In: Burland WL, Simkins MA, editors. Exerpta Medica: Amsterdam, 1977: 358–66
Kimberly RP, Weinberg H, Rudd E. Great reduction in renal function associated with cimetidine. Arthritis Rheumatol 1980; 23: 614
Dubb JW, Stote RM, Familiar RG, et al. Effect of cimetidine on renal function in normal man. Clin Pharmacol Ther 1978; 24: 76–83
McKinney TD, Myers P, Speeg KV. Cimetidine secretion by rabbit renal tubules in vitro. Am J Physiol 1981; 241: F69–76
Czuba MA, Morgan DJ, Ching MS, et al. Ontogeny of fetal renal organic cation excretion: A study with cimetidine and ranitidine during the latter half of gestation in pregnant ewe. J Pharmacol Exp Ther 1990; 255: 1177–82
Rocci ML, Vlasses PH, Ferguson RK. Creatinine serum concentrations and H2-receptor antagonists. Clin Nephrol 1984; 22: 214–5
Pachon J, Lorber MI, Bia M. Effects of H2-receptor antagonists on renal function in cyclosporin-treated renal transplant patients. Transplantation 1989; 47: 254–9
Neelakantappa K, Gallo GR, Lowenstein J. Ranitidineassociated interstitial nephritis and Fanconi syndrome. Am J Kidney Dis 1993; 22: 333–6
Kirch W, Hoensch H, Janisch HD. Interactions and non-interactions with ranitidine. Clin Pharmacokinet 1984; 9: 493–510
Feldman M, Burton ME. Histamine-2-receptor antagonists. Standard therapy for acid-peptic diseases. N Engl J Med 1990; 323: 1672–80
Selkurt EE. Influence of histamine on electrolyte and water handling of the canine kidney. Proc Soc Exp Biol Med 1977; 155: 605–10
Selkurt EE, Hockel GM, Weinberger MH. Some evidence for interrelationship of histamine and prostaglandin on renal function. Proc Soc Exp Biol Med 1979; 160: 328–34
Morley JJ, Ballou SP. Cimetidine-induced elevation of serum creatinine in a patient with lupus nephritis. J Rheumatol 1983; 10: 520–22
McGowan WR, Vermillion SE. Acute interstitial nephritis related to cimetidine therapy. Gastroenterology 1980; 79: 746–49
Hake DH. Interstitial nephritis and cimetidine. Ann Intern Med 1981; 94: 416
Richman AV, Narayan JL, Hirschfield JS. Acute interstitial nephritis and acute renal failure associated with cimetidine therapy. Am J Med 1981; 70: 1272–4
Rudnick MR, Bastl CP, Elfenbein IB, et al. Cimetidine-induced renal failure. Ann Intern Med 1982; 96: 180–2
Payne CR, Ackrill P, Ralston AJ. Acute renal failure and rise in alkaline phosphatase activity caused by cimetidine. BMJ 1982; 285: 100
Ali N, Hamilton DV, Pryor JS, et al. Safety of cimetidine. BMJ 1985; 291: 1426–7
Pitone JM, Sautoro JJ, Biondi RJ, et al. Cimetidine-induced acute interstitial nephritis. Am J Gastroenterol 1982; 77: 169–71
Potter PH, Westby RG. Interstitial nephritis after cimetidine but not ranitidine. JAMA 1983; 249: 351
Kaye WA, Passero MA, Solomon RJ, et al. Cimetidine-induced interstitial nephritis with response to prednisone therapy. Arch Intern Med 1983; 143: 811–2
Watson AJS, Dalbow MH, Stachura I, et al. Immunologic studies in cimetidine-induced nephropathy and polymyositis. N Engl J Med 1983; 308: 142–5
Ozawa TT, Smith P, Vance D, et al. Acute interstitial nephritis induced by cimetidine. J Tenn Med Assoc 1987; 80: 411–3
Mullen PJ. Polyuria and weight-loss associated with cimetidine. Postgrad Med J 1992; 68: 771
Koarada S, Nagano Y, Sakemi T et al. Acase of acute interstitial nephritis and nonoliguria acute renal failure induced by cimetidine [in Japanese]. Nippon Jinzo Gakkai Shi 1992; 34(11); 1227–32
Kitahara T, Hiromura K, Sugawara M, et al. Acase of cimetidineinduced acute tubulointerstitial nephritis associated with antineutrophil cytoplasmic antibody. Am J Kidney Dis 1999; 33: E7
Freeman HJ. Ranitidine-associated interstitial nephritis in a patient with celiac sprue. Can J Gastroenterol 1988; 2: 35–6
Gaughan WJ, Sheth VR, Francos GC, et al. Ranitidine-induced acute interstitial nephritis with epithelial cell foot process fusion. Am J Kidney Dis 1993; 22: 337–40
Karras DJ. Severe low back pain secondary to acute interstitial nephritis following administration of ranitidine. Am J Emerg Med 1994; 12: 67–8
Hirayama K, Hanatsuka K, Ikeuchi T, et al. Famotidine-induced acute interstitial nephritis. Nephrol Dial Transplant 1998; 13: 2636–8
Ooi BS, Jao W, First MR. Acute interstitial nephritis. Am J Med 1975; 59: 614–29
Galpin JE, Shinaberger JH, Stanley TM, et al. Acute interstitial nephritis due to methicillin. Am J Med 1978; 65: 756–65
Nolan CRI, Anger MS, Kelleher SP. Eosinophiluria: a new method of detection and definition of the clinical spectrum. N Engl J Med 1986; 315: 1516–9
Ruffing KA, Hoppes P, Blend D, et al. Eosinophils in urine revisited. Clin Nephrol 1994; 41: 163–6
Katz SM, Capaldo R, Everts EA, et al. Association with reversible renal failure and acute interstitial nephritis. JAMA 1982; 246: 243–5
Abraham PA, Keane WF. Glomerular and interstitial disease induced by nonsteroidal anti-inflammatory drugs. Am J Nephrol 1984; 4: 1–6
Shibata M, Hoon D, Okun E, et al. Modulation of histamine type receptors on CD8+T cells by interleukin-2 and cimetidine. Int Arch Allergy Immunol 1992; 97: 8–16
Hellstrand K, Asea A, Hermodsson S. Histaminergic regulation of antibody-dependent cellular cytotoxicity of granulocytes, monocytes, and natural killer cells. J Leucocyte Biol 1994; 55: 392–7
Hahm KB, Kim WH, Lee SI, et al. Comparison of immunomodulative effects of the histamine -2 receptor antagonists cimetidine, ranitidine, and famotidine on peripheral blood mononuclear cells in gastric cancer patients. Scand J Gastroenterol 1995; 30: 265–71
Hahm KB, Park IS, Kim HC, et al. Comparison of antiproliferative effects of the histamine-2 receptor antagonists, cimetidine, ranitidine, and famotidine, in gastric cancer cells. Int J Immunopharmacol 1996; 18: 397–9
Fujimoto M, Kimata H. Histamine inhibits immunoglobulin production via histamine H2 receptors without affecting cell growth in human-cells. Clin Immunol Immunopathol 1994; 73: 96–102
Burton C, Scheinmann P, Fray A, et al. Ranitidine. N Engl J Med 1984; 310: 1603
Elenkov IJ, Webster E, Papanicolaou DA, et al. Histamine potently suppresses human L-12 and stimulates L-10 production via H2 receptors. J Immunol 1998; 161: 2586–93
Kumar A. Cimetidine: an immunomodulator. Drug Intel Clin Pharm 1990; 24: 289–95
Gifford RR, Tilberg AF. Histamine type-2 receptor antagonist immune modulation. Cimetidine and ranitidine increase interleukin-2 production. Surgery 1987; 102: 242–7
Katoh J, Kouji T, Sato W, et al. Cimetidine and immunoreactivity. Lancet 1996; 348: 404–5
Adams WJ, Morris DL. Pilot study: cimetidine enhances lymphocyte infilltration of human colorectal carcinoma: results of a small randomized control trial. Cancer 1997; 80: 15–21
Anlar B, Gucuyener K, Imir T. Cimetidine as an immunomodulator in subacute sclerosing panencephalitis: a double-blind, placebo-controlled study. Pediatr Infect Dis J 1993; 12: 578–81
Estelle F, Simons R. Principles and practice. In: Middleton E, editor. Allergy. Mosby: St Louis, 1998: 612–37
Matthiesen L, Berg G, Ernerudh J, et al. Lymphocyte subset and mitogen stimulation of blood lymphocytes in preeclampsia. Am J Reprod Immunol 1999; 41: 192–203
Adler SG, Cohen AH, Border WA. Hypersensitivity phenomena and the kidney: role of drugs and enviromental agents. Am J Kidney Dis 1985; 5: 75–96
Knapp AB, Grimshaw RS, Goldfarb JP. Cimetidine-induced anaphylaxis. Ann Intern Med 1982; 97: 138–40
Hiraide A, Yoshioka T, Ohshima S. gE -mediated drug fever due to histamine H2-receptor blockers. Drug Saf 1990; 5: 455–7
Almroth G, Enestrom S, Hed J, et al. Autoantibodies to leucocyte antigens in hydralazine-associated nephritis. J Intern Med 1992; 231: 37–42
Singer S, Parry RG, Deodhar HA, et al. Acute interstitial nephritis, omeprazole and autineutrophil cytoplasmic antibodies. Clin Nephrol 1994; 42: 280
Shih DJ, Korbet SM, Rydel JJ, et al. Renal vasculitis associated with ciprofloxacin. Am J Kidney Dis 1995; 26: 516–9
Avella J, Binder HJ, Madsen JE, et al. Effect of histamine H2-receptor antagonists on delayed hypersensitivity. Lancet 1978; I: 624–6
Daman LA, Rosenberg EW. Acquired tolerance to dinitro-chlorobenzene reversed by cimetidine. Lancet 1977; II: 1087
Jorizzo JL, Sams WM, Jegasothy BU. Cimetidine as an immunomodulator: chronic mucocutaneous candidiasis as a model. Ann Intern Med 1980; 92: 192–5
Rocklin RD. Modulation of cellular immune responses in vivo and in vitro by histamine receptor bearing lymphocytes. J Clin Invest 1976; 57: 1051–8
Van Zwieten MJ, Leber PD, Bhan AK, et al. Experimental cellmediated interstitial nephritis with exogenous antigens. J Immunol 1977; 118: 589–93
McCluskey RT, Bhan AK. Cell-mediated immunity in renal disease. Human Pathol 1986; 17: 146–53
McCluskey RT, Colvin RB. Immunological aspects of renal tubular and interstitial diseases. Ann Rev Med 1978; 29: 191–203
Husby G, Tung KSK, Williams Jr RC. Characterization of renal tissue lymphocytes in patients with interstitial nephritis. Am J Med 1981; 70: 31–8
Stachura I, Jayakumar S, Bourke E. T and B lymphocyte subsets in fenoprofen nephropathy. Am J Med 1983; 75: 9–16
Stachura I, Si L, Madan E, et al. Mononuclear cell subsets in human renal disease enumeration in tissue sections with monoclonal antibodies. Clin Immunol Immunopathol 1984; 30: 362–73
Pamukcu R, Moorthy AV, Singer JR, et al. Idiopathic acute interstitial nephritis: characterization of the infiltrating cells in the renal interstitium as T helper lymphocytes. sAm J Kidney Dis 1984; 4: 24–9
Boucher A, Droz D, Adafer E, et al. Characterization of mononuclear cell subsets in renal cellular interstitial infiltrates. Kidney Int 1986; 29: 1043–9
Evans RL, Faldetta TJ, Humphreys RE, et al. Peripheral human T cells sensitized in mixed leukocyte culture synthesize and express Ia-like antigens. J Exp Med 1978; 148: 1440–5
Laberke H-G. Treatment of acute interstitial nephritis. Klin Wochenschr 1980; 58: 531–2
Pusey CD, Saltissi D, Bloodworth L, et al. Drug associated acute interstitial nephritis: clinical and pathological features and the response to high dose steroid therapy. Q J Med 1983; 52: 194–211
Zimmerman HJ, Jacob L, Bassan H, et al. Effects of H2-blocking agents in hepatcytes in vitro: correlation with potential for causing hepatic disease in patients. Proc Soc Exp Biol Med 1986; 182: 511–4
Willson RA, Hall T, Hart J. Oxmetidine (H2 receptor antagonist) induced cytotoxicity in isolated rat hepatocytes. J Appl Toxicol 1988; 8: 223–5
Andrade RJ, Lucena MI, Martin-Vivaldi R, et al. Acute liver injury associated with the use of ebrotidine, a new H2-receptor antagonist. J Hepatol 1999; 31: 641–6
Dobbs JH, Muir JG, Smith RN. H2-antagonists and hepatitis. Ann Intern Med 1986; 105: 803
Rodriguez GLA, Wallander MA, Stricker BH. The risk of acute liver injury associated with cimetidine and other acid-suppressing anti-ulcer drugs. Br J Clin Pharmacol 1997; 43: 183–8
Hirono S, Gohda E, Tsubouchi H, et al. Effect of histamine H2-receptor antagonists on DNA synthesis in adult rat hepatocytes in primary culture. Cimetidine enhanced hepatocytes proliferation stimulated with insulin and epidermal growth factor. Pharmacol Res Commun 1987; 19: 479–99
Delpre G, Kadish U, Livni E. Hepatitis following cimetidine administration. Am J Med Sci 1982; 283: 153–6
Lilly M, Hitch DC, Javitt NB. Cimetidine cholestatic jaundice in children. J Surg Res 1978; 24: 384–7
Villeneuve JP, Warner HA. Cimetidine hepatitis. Gastroenterology 1979; 77: 143–4
Schwartz JT, Gyorkey F, Graham DY. Cimetidine hepatitis. J Clin Gastroenterol 1986; 8: 681–6
Boyd PT, Lepre F, Dickey JD. Chronic active hepatitis associated with cimetidine. BMJ 1989; 298: 324–5
Lorenzini I, Jezequel AM, Orlandi F. Cimetidine-induced hepatitis. Electron microscopic observations and clinical pattern of liver injury. Digest Dis Sci 1981; 26: 275–80
Cleator IGM. Adverse effects of ranitidine therapy. Can Med Assoc J 1983; 129: 405
Proctor JD. Hepatitis associated with ranitidine. JAMA 1984; 251: 1554
Souza-Lima JAS. Hepatitis associated with ranitidine. Ann Intern Med 1984; 101: 207–8
Offit K, Sojka DA. Ranitidine. N Engl J Med 1984; 310: 1603
Black M, Scott WE, Kanter R. Possible ranitidine hepatotoxicity. Ann Intern Med 1989; 101: 208–10
Barr GD, Piper DW. Possible ranitidine hepatitis. Med J Aust 1981; 2: 421
Hiesse C, Cantarovich M, Santelli C, et al. Ranitidine hepatotoxicity in renal transplant patient. Lancet 1985; I: 1280
Graham DY, Opekun AR, Smith JL, et al. Ranitidine and hepatotoxicity. Ann Intern Med 1985; 102: 416
Lauritsen K, Havelund T, Rask-Madsen J. Ranitidine and hepatotoxicity. Lancet 1984; II: 1471
Hegarty JE. Ranitidine and hepatotoxicity. Lancet 1985; I: 223
Zeldis JB, Friedman LS, Isselbacher KJ. Ranitidine. N Engl J Med 1984; 310: 1605–6
Jack D, Smith RN, Wise PJ. Ranitidine [letter]. N Engl J Med 1984; 310: 1606
Devuyst D, Lefebvre C, Geubel A, et al. Acute cholestatic hepatitis with rash and hypereosinophilia. Acta Clin Belgium 1993; 48: 109–14
Karachalios GN. Ranitidine and hepatitis. Ann Intern Med 1985; 103: 634–5
Ramrakhiani S, Brunt EM, Bacon BR. Possible cholestatic injury from ranitidine with a review of the literature. Am J Gastroenterol 1998; 93: 822–6
Dukes MNG. Meylers side effects of drugs. 13th edition. Amsterdam: Elsevier, 1996
Cherqui B, Desaint B, Legendre C, et al. Hepatite mortelle chez une patiente traitee par la ranitidine. Gastroenterol Clin Biol 1989; 13: 952–3
Ribeiro J, Lucas M, Baptista A, et al. Fatal hepatitis associated with ranitidine. Am J Gastroenterol 2000; 95: 559–60
Hashimoto F, Davis RL, Egli D. Hepatitis following treatments with famotidine and then cimetidine. Ann Pharmacother 1994; 28: 37–9
Ament PW, Roth JD, Fox CJ. Famotidine-induced mixed hepatocellular jaundice. Ann Pharmacother 1994; 28: 40–2
Lee sWM. Drug-induced hepatotoxicity. N Engl J Med 1995; 333: 118–27
Farrell GC. Liver disease caused by drugs, anesthetics and toxins. In: Feldman M Scharschmidt BF, Sleisenger MH, editors. Sleiseuger and Fordtran’s gastrointestinal and liver disease. 6th ed. Philadelphia: W.B. Saunders Company, 1998: 1221–52
Maria VA, Victorino RM. Diagnostic value of specific T cell reactivity to drugs in 95 cases of drug indicued liver injury. Gut 1997; 41: 534–40
Cao J, Lu J, Wu F, et al. Effects of several drugs on the liver injury induced by delayed-type hypersensitvity to picryl chloride by regulating suppressor or helper T cells. Pharmacol Res 1999; 39: 97–102
Tyden G, Thulin L, Myberg B. The effect of cimetidine on liver blood flow in anesthetized men. Acta Chir Scand 1983; 149: 303–5
Carfagna MA, Held SD, Kedderis GL. Furan-induced cytolethality in isolated rat hepatocytes: correspondence with in vivo dosimetry. Toxicol Appl Pharmacol 1993; 123: 265–73
Acknowledgements
We would like to thank Dr Patrick Purcell for information from the Australian Adverse Drug Reactions Advisory Committee (ADRAC), Dr Michael Falk for a case report, and Professor Allan J McLean, Professor Paul Gatenby and Kim Forsyth for assistance with the manuscript.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Fisher, A.A., Le Couteur, D.G. Nephrotoxicity and Hepatotoxicity of Histamine H2 Receptor Antagonists. Drug-Safety 24, 39–57 (2001). https://doi.org/10.2165/00002018-200124010-00004
Published:
Issue Date:
DOI: https://doi.org/10.2165/00002018-200124010-00004